Teleflex to sell Telair's Actuation business to TransDigm

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technology products, today announced that it has entered into a definitive agreement to sell the Actuation business of its subsidiary Telair International Incorporated to TransDigm Group, Incorporated (NYSE: TDG) for approximately $94 million. The transaction is subject to receipt of Hart-Scott-Rodino approval and other customary closing conditions and is expected to close by the end of 2010.

“Today we took another step towards achieving our strategic objective of becoming a pure-play medical technology company. This move allows us to continue to focus on the development of our portfolio of quality medical technology products which improve outcomes and patient and provider safety”

Actuation, which generated net revenues of approximately $24 million during the twelve months ended September 26, 2010, is a leading global provider of aftermarket service and support for commercial and military aircraft actuators, serving all major OEMs and airlines.

"Today we took another step towards achieving our strategic objective of becoming a pure-play medical technology company. This move allows us to continue to focus on the development of our portfolio of quality medical technology products which improve outcomes and patient and provider safety," stated Jeffrey P. Black, Chairman and Chief Executive Officer.

The Actuation business was expected to contribute approximately $25 million in annual revenues and approximately $0.15 per diluted share in annual earnings for 2010. As a result, the Company is adjusting its financial estimates for 2010 revenue from approximately $1.8 billion to approximately $1.78 billion; and for 2010 diluted earnings per share from continuing operations excluding special items from a range of $4.00 to $4.10 to a range of $3.85 to $3.95.

Actuation will be reflected as a discontinued operation in Teleflex's future consolidated financial statements.

SOURCE Teleflex Incorporated

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global Alzheimer’s Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study